Management of Borderline Resectable Pancreatic Cancer

被引:49
|
作者
Katz, Matthew H. G. [1 ]
Crane, Christopher H. [2 ]
Varadhachary, Gauri [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
关键词
GEMCITABINE-BASED CHEMORADIATION; EXPERT CONSENSUS STATEMENT; PREOPERATIVE GEMCITABINE; RADIATION-THERAPY; MULTIINSTITUTIONAL PHASE-2; NEOADJUVANT GEMCITABINE; CONTROLLED-TRIAL; DOSE-ESCALATION; ADENOCARCINOMA; CHEMOTHERAPY;
D O I
10.1016/j.semradonc.2013.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Borderline resectable pancreatic cancers are those that, although technically resectable, are at high risk for margin-positive resection following surgery de novo. Generally, such cancers are characterized by localized primary tumors that involve the mesenteric vasculature to a limited degree and that may require venous or hepatic arterial resection at pancreatectomy. In this article, we review diagnosis and staging algorithms, pretreatment strategies, and multidisciplinary treatment protocols for patients with this stage of disease. The rationale for and results following treatment with neoadjuvant chemotherapy and chemoradiation and subsequent surgical resection of the primary tumor are described in detail and existing data are reviewed. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:105 / 112
页数:8
相关论文
共 50 条
  • [21] Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
    Gauri R. Varadhachary
    Eric P. Tamm
    James L. Abbruzzese
    Henry Q. Xiong
    Christopher H. Crane
    Huamin Wang
    Jeffrey E. Lee
    Peter W. T. Pisters
    Douglas B. Evans
    Robert A. Wolff
    Annals of Surgical Oncology, 2006, 13 : 1035 - 1046
  • [22] Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy
    Varadhachary, Gauri R.
    Tamm, Eric P.
    Abbruzzese, James L.
    Xiong, Henry Q.
    Crane, Christopher H.
    Wang, Huamin
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Evans, Douglas B.
    Wolff, Robert A.
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (08) : 1035 - 1046
  • [23] New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer
    Jutric, Zeljka
    Melstrom, Laleh G.
    ONCOLOGY-NEW YORK, 2017, 31 (06): : 443 - 452
  • [24] Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
    Shaib, Walid L.
    Ip, Andrew
    Cardona, Kenneth
    Alese, Olatunji B.
    Maithel, Shishir K.
    Kooby, David
    Landry, Jerome
    El-Rayes, Bassel F.
    ONCOLOGIST, 2016, 21 (02): : 178 - 187
  • [25] Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma
    Schwarz, Lilian
    Katz, Matthew Harold G.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (04) : 727 - +
  • [26] Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer
    Kharofa, Jordan
    Tsai, Susan
    Kelly, Tracy
    Wood, Clint
    George, Ben
    Ritch, Paul
    Wiebe, Lauren
    Christians, Kathleen
    Evans, Douglas B.
    Erickson, Beth
    RADIOTHERAPY AND ONCOLOGY, 2014, 113 (01) : 41 - 46
  • [27] Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease
    Soloff, Erik V.
    Zaheer, Atif
    Meier, Jeffrey
    Zins, Marc
    Tamm, Eric P.
    ABDOMINAL RADIOLOGY, 2018, 43 (02) : 301 - 313
  • [28] Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease
    Erik V. Soloff
    Atif Zaheer
    Jeffrey Meier
    Marc Zins
    Eric P. Tamm
    Abdominal Radiology, 2018, 43 : 301 - 313
  • [29] Strategy of Neoadjuvant Therapy for Resectable/Borderline Resectable Pancreatic Cancer
    Hashimoto, D.
    Satoi, S.
    Yamamoto, T.
    Yamaki, S.
    Hirooka, S.
    Ishida, M.
    Ikeura, T.
    Sekimoto, M.
    PANCREAS, 2021, 50 (07) : 1064 - 1064
  • [30] Neoadjuvant therapy in borderline resectable and resectable pancreatic cancer.
    Dhamija, Kriti
    Awuah, Kojo-Frimpong B.
    Marwaha, Alexander
    Kharoud, Harmeet
    Monga, Dulabh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 735 - 735